Granulocyte colony-stimulating factor – why it is worth to use filgrastim? Review article
Article Sidebar
Published:
Sep 30, 2020
Keywords:
neutropenia, febrile neutropenia, granulocyte colony-stimulating factor
Main Article Content
Abstract
Neutropenia fever is one of the most common side effect of chemotherapy and might lead to severe complications and death. The use of granulocyte colony-stimulating factors in primary and secondary prevention of neutropenia fever leads to reduction in hospitalization time and significantly affects the decrease in treatment-related mortality. Factors stimulating granulocyte colonies prevent the need to reduce the dose of the cytostatics and to extend the intervals between the treatment cycles, which increases the effectiveness of therapy.
Article Details
How to Cite
Ścirka , N., & Kubiatowski , T. (2020). Granulocyte colony-stimulating factor – why it is worth to use filgrastim?. Medycyna Faktow (J EBM), 13(3(48), 285-288. https://doi.org/10.24292/01.MF.0320.2
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in Neutropenia. J Immunol. 2015; 195(4): 1341-9. http://doi.org/10.4049/jimmunol.1500861.
2. Dzietczenia J. Profilaktyka neutropenii u pacjentów w wieku podeszłym. Acta Haematologica Polonica. 2013; 44(2): 124-9. http://doi.org/10.1016/j.achaem.2013.02.013.
3. Klastersky J. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27(suppl 5): v111-v118. http://doi.org/10.1093/annonc/mdw325.
4. Sung L, Nathan PC, Alibhai SM et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007; 147: 400-11.
5. Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. J Natl Compr Canc Netw. 2015; 13(1): e1-e7. http://doi.org/10.6004/jnccn.2015.0014.
6. Smith C, Khatcheressian J, Lyman G et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24: 3187-205.
7. Bennett CL, Djulbegovic B, Norris LB et al. Colony-stimulating Factors for Febrile Neutropenia During Cancer Therapy. N Engl J Med. 2013, 368: 1131-9.
8. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991; 325: 164-70.
9. Caggiano V, Weiss RV, Rickert TS et al. Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005; 103: 1916-24.
10. Dinan MA, Hirsch BR, Lyman GH. Management of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value. J Natl Compr Canc Netw. 2020; 13(1): e1-e7. https://doi.org/10.6004/jnccn.2015.0014.
11. Guan WJ, Ni ZY, Hu Yu et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 [Epub ahead of print]. https://doi.org/10.1056/NEJMoa2002032.
12. Wysocki PJ, Kwinta Ł, Potocki P et al. Leczenie systemowe chorych na nowotwory lite w trakcie pandemii SARS-CoV-2. Onkol Prakt Klin Edu. 2020; 6(2): 57-68.
13. Cooper K, Madan J, Whyte S et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis BMC. Cancer. 2011; 11: 404-15.
2. Dzietczenia J. Profilaktyka neutropenii u pacjentów w wieku podeszłym. Acta Haematologica Polonica. 2013; 44(2): 124-9. http://doi.org/10.1016/j.achaem.2013.02.013.
3. Klastersky J. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27(suppl 5): v111-v118. http://doi.org/10.1093/annonc/mdw325.
4. Sung L, Nathan PC, Alibhai SM et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007; 147: 400-11.
5. Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. J Natl Compr Canc Netw. 2015; 13(1): e1-e7. http://doi.org/10.6004/jnccn.2015.0014.
6. Smith C, Khatcheressian J, Lyman G et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24: 3187-205.
7. Bennett CL, Djulbegovic B, Norris LB et al. Colony-stimulating Factors for Febrile Neutropenia During Cancer Therapy. N Engl J Med. 2013, 368: 1131-9.
8. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991; 325: 164-70.
9. Caggiano V, Weiss RV, Rickert TS et al. Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005; 103: 1916-24.
10. Dinan MA, Hirsch BR, Lyman GH. Management of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value. J Natl Compr Canc Netw. 2020; 13(1): e1-e7. https://doi.org/10.6004/jnccn.2015.0014.
11. Guan WJ, Ni ZY, Hu Yu et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 [Epub ahead of print]. https://doi.org/10.1056/NEJMoa2002032.
12. Wysocki PJ, Kwinta Ł, Potocki P et al. Leczenie systemowe chorych na nowotwory lite w trakcie pandemii SARS-CoV-2. Onkol Prakt Klin Edu. 2020; 6(2): 57-68.
13. Cooper K, Madan J, Whyte S et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis BMC. Cancer. 2011; 11: 404-15.